NASDAQ:RVPH Reviva Pharmaceuticals (RVPH) Stock Forecast, Price & News $6.78 +0.33 (+5.12%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$6.31▼$6.9250-Day Range$3.93▼$8.5552-Week Range$0.53▼$9.25Volume180,873 shsAverage Volume148,407 shsMarket Capitalization$138.65 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Reviva Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside165.5% Upside$18.00 Price TargetShort InterestBearish7.97% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.01) to ($0.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.49 out of 5 starsMedical Sector834th out of 983 stocksPharmaceutical Preparations Industry418th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingReviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.00, Reviva Pharmaceuticals has a forecasted upside of 165.5% from its current price of $6.78.Amount of Analyst CoverageReviva Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted7.97% of the outstanding shares of Reviva Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverReviva Pharmaceuticals has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in Reviva Pharmaceuticals has recently increased by 20.74%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldReviva Pharmaceuticals does not currently pay a dividend.Dividend GrowthReviva Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RVPH. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 14 people have searched for RVPH on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders32.06% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.29% of the stock of Reviva Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($1.01) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reviva Pharmaceuticals is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reviva Pharmaceuticals is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReviva Pharmaceuticals has a P/B Ratio of 24.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Reviva Pharmaceuticals (NASDAQ:RVPH) StockReviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.Read More Receive RVPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RVPH Stock News HeadlinesMay 25, 2023 | finance.yahoo.comReviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research ArchivesMay 22, 2023 | finance.yahoo.comReviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual MeetingJune 2, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 19, 2023 | finance.yahoo.comReviva Pharmaceuticals Joins Webull Corporate Communications Service PlatformMay 18, 2023 | finance.yahoo.comReviva Pharmaceuticals to Present at Upcoming Investor Conferences in May 2023May 17, 2023 | finance.yahoo.comRVPH: Psoriasis IND ExpectedMay 16, 2023 | finanznachrichten.deReviva Pharmaceuticals: Reviva Reports First Quarter 2023 Financial Results and Recent Business HighlightsMay 15, 2023 | finance.yahoo.comReviva Reports First Quarter 2023 Financial Results and Recent Business HighlightsJune 2, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 12, 2023 | finance.yahoo.comReviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor ConferenceMay 11, 2023 | finance.yahoo.comReviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical DataMay 5, 2023 | americanbankingnews.comReviva Pharmaceuticals (NASDAQ:RVPH) PT Raised to $18.00May 4, 2023 | finance.yahoo.comReviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023May 3, 2023 | msn.comMaxim Group Maintains Reviva Pharmaceuticals Holdings (RVPH) Buy RecommendationMay 1, 2023 | finance.yahoo.comReviva Pharmaceuticals Presented Foundational Preclinical Data on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual SOBP and Publication in Medical Research ArchivesApril 21, 2023 | msn.comUnusual Call Option Trade in Reviva Pharmaceuticals Holdings (RVPH) Worth $30.00KApril 20, 2023 | finance.yahoo.comReviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological PsychiatryApril 8, 2023 | americanbankingnews.comFY2023 EPS Estimates for Reviva Pharmaceuticals Holdings, Inc. Decreased by Analyst (NASDAQ:RVPH)April 8, 2023 | americanbankingnews.comReviva Pharmaceuticals Holdings, Inc. Forecasted to Post Q1 2023 Earnings of ($0.36) Per Share (NASDAQ:RVPH)April 6, 2023 | americanbankingnews.comReviva Pharmaceuticals (NASDAQ:RVPH) Stock Rating Reaffirmed by HC WainwrightApril 5, 2023 | americanbankingnews.comResearch Analysts Set Expectations for Reviva Pharmaceuticals Holdings, Inc.'s Q1 2024 Earnings (NASDAQ:RVPH)April 4, 2023 | msn.comHC Wainwright & Co. Reiterates Reviva Pharmaceuticals Holdings (RVPH) Buy RecommendationApril 4, 2023 | finance.yahoo.comRVPH: RECOVER Parallel Studies CompleteApril 1, 2023 | markets.businessinsider.comReviva Pharmaceuticals Holdings (RVPH) Receives a Buy from Maxim GroupMarch 30, 2023 | finance.yahoo.comReviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022 Financial Results and Recent Business HighlightsMarch 30, 2023 | finance.yahoo.comReviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022 Financial Results and Recent Business HighlightsMarch 10, 2023 | finance.yahoo.comRVPH: Brilaroxazine Enthusiasm AboundsSee More Headlines RVPH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVPH Company Calendar Last Earnings11/15/2021Today6/02/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RVPH CUSIPN/A CIK1742927 Webwww.revivapharma.com Phone(408) 501-8881FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.00 High Stock Price Forecast$20.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+179.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-172.98% Return on Assets-123.26% Debt Debt-to-Equity RatioN/A Current Ratio1.97 Quick Ratio1.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book23.04Miscellaneous Outstanding Shares20,450,000Free Float13,895,000Market Cap$131.90 million OptionableNot Optionable Beta0.13 Key ExecutivesLaxminarayan BhatPresident, Chief Executive Officer & DirectorNarayan PrabhuChief Financial OfficerKey CompetitorsCytomX TherapeuticsNASDAQ:CTMXCapricor TherapeuticsNASDAQ:CAPRSeelos TherapeuticsNASDAQ:SEELViveon Health AcquisitionNYSE:VHAQOncolytics BiotechNASDAQ:ONCYView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPBought 29,100 shares on 5/16/2023Ownership: 0.000%Colony Group LLCBought 93,000 shares on 5/16/2023Ownership: 0.455%Sabby Management LLCBought 10 shares on 5/16/2023Ownership: 0.000%Two Sigma Investments LPSold 30,635 shares on 5/15/2023Ownership: 0.080%Belvedere Trading LLCBought 3,500 shares on 5/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions RVPH Stock - Frequently Asked Questions Should I buy or sell Reviva Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVPH shares. View RVPH analyst ratings or view top-rated stocks. What is Reviva Pharmaceuticals' stock price forecast for 2023? 3 equities research analysts have issued 12-month price targets for Reviva Pharmaceuticals' shares. Their RVPH share price forecasts range from $16.00 to $20.00. On average, they anticipate the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 179.1% from the stock's current price. View analysts price targets for RVPH or view top-rated stocks among Wall Street analysts. How have RVPH shares performed in 2023? Reviva Pharmaceuticals' stock was trading at $4.25 at the beginning of the year. Since then, RVPH shares have increased by 51.8% and is now trading at $6.45. View the best growth stocks for 2023 here. Are investors shorting Reviva Pharmaceuticals? Reviva Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,630,000 shares, an increase of 20.7% from the April 30th total of 1,350,000 shares. Based on an average trading volume of 150,600 shares, the short-interest ratio is currently 10.8 days. View Reviva Pharmaceuticals' Short Interest. When is Reviva Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our RVPH earnings forecast. How were Reviva Pharmaceuticals' earnings last quarter? Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) announced its earnings results on Monday, November, 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.11. What is Reviva Pharmaceuticals' stock symbol? Reviva Pharmaceuticals trades on the NASDAQ under the ticker symbol "RVPH." Who are Reviva Pharmaceuticals' major shareholders? Reviva Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Susquehanna International Group LLP (0.00%), Colony Group LLC (0.45%), Two Sigma Investments LP (0.08%), Belvedere Trading LLC (0.00%), Group One Trading L.P. (0.00%) and Sabby Management LLC (0.00%). Insiders that own company stock include Prabhu Narayan, Purav Patel and Vedanta Partners, Llc. View institutional ownership trends. How do I buy shares of Reviva Pharmaceuticals? Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Reviva Pharmaceuticals' stock price today? One share of RVPH stock can currently be purchased for approximately $6.45. How much money does Reviva Pharmaceuticals make? Reviva Pharmaceuticals (NASDAQ:RVPH) has a market capitalization of $131.90 million. The company earns $-24,340,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. How can I contact Reviva Pharmaceuticals? Reviva Pharmaceuticals' mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The official website for the company is www.revivapharma.com. The company can be reached via phone at (408) 501-8881 or via email at ir.revivapharma.com. This page (NASDAQ:RVPH) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.